Cargando…

Proteomic quantification of receptor tyrosine kinases involved in the development and progression of colorectal cancer liver metastasis

INTRODUCTION: Alterations in expression and activity of human receptor tyrosine kinases (RTKs) are associated with cancer progression and in response to therapeutic intervention. METHODS: Thus, protein abundance of 21 RTKs was assessed in 15 healthy and 18 cancerous liver samples [2 primary and 16 c...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasilogianni, Areti-Maria, Al-Majdoub, Zubida M., Achour, Brahim, Peters, Sheila Annie, Rostami-Hodjegan, Amin, Barber, Jill
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986493/
https://www.ncbi.nlm.nih.gov/pubmed/36890818
http://dx.doi.org/10.3389/fonc.2023.1010563
_version_ 1784901180274507776
author Vasilogianni, Areti-Maria
Al-Majdoub, Zubida M.
Achour, Brahim
Peters, Sheila Annie
Rostami-Hodjegan, Amin
Barber, Jill
author_facet Vasilogianni, Areti-Maria
Al-Majdoub, Zubida M.
Achour, Brahim
Peters, Sheila Annie
Rostami-Hodjegan, Amin
Barber, Jill
author_sort Vasilogianni, Areti-Maria
collection PubMed
description INTRODUCTION: Alterations in expression and activity of human receptor tyrosine kinases (RTKs) are associated with cancer progression and in response to therapeutic intervention. METHODS: Thus, protein abundance of 21 RTKs was assessed in 15 healthy and 18 cancerous liver samples [2 primary and 16 colorectal cancer liver metastasis (CRLM)] matched with non-tumorous (histologically normal) tissue, by a validated QconCAT-based targeted proteomic approach. RESULTS: It was demonstrated, for the first time, that the abundance of EGFR, INSR, VGFR3 and AXL, is lower in tumours relative to livers from healthy individuals whilst the opposite is true for IGF1R. EPHA2 was upregulated in tumour compared with histologically normal tissue surrounding it. PGFRB levels were higher in tumours relative to both histologically normal tissue surrounding tumour and tissues taken from healthy individuals. The abundances of VGFR1/2, PGFRA, KIT, CSF1R, FLT3, FGFR1/3, ERBB2, NTRK2, TIE2, RET, and MET were, however, comparable in all samples. Statistically significant, but moderate correlations were observed (Rs > 0.50, p < 0.05) for EGFR with INSR and KIT. FGFR2 correlated with PGFRA and VGFR1 with NTRK2 in healthy livers. In non-tumorous (histologically normal) tissues from cancer patients, there were correlations between TIE2 and FGFR1, EPHA2 and VGFR3, FGFR3 and PGFRA (p < 0.05). EGFR correlated with INSR, ERBB2, KIT and EGFR, and KIT with AXL and FGFR2. In tumours, CSF1R correlated with AXL, EPHA2 with PGFRA, and NTRK2 with PGFRB and AXL. Sex, liver lobe and body mass index of donors had no impact on the abundance of RTKs, although donor age showed some correlations. RET was the most abundant of these kinases in non-tumorous tissues (~35%), while PGFRB was the most abundant RTK in tumours (~47%). Several correlations were also observed between the abundance of RTKs and proteins relevant to drug pharmacokinetics (enzymes and transporters). DISCUSSION: DiscussionThis study quantified perturbation to the abundance of several RTKs in cancer and the value generated in this study can be used as input to systems biology models defining liver cancer metastases and biomarkers of its progression.
format Online
Article
Text
id pubmed-9986493
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99864932023-03-07 Proteomic quantification of receptor tyrosine kinases involved in the development and progression of colorectal cancer liver metastasis Vasilogianni, Areti-Maria Al-Majdoub, Zubida M. Achour, Brahim Peters, Sheila Annie Rostami-Hodjegan, Amin Barber, Jill Front Oncol Oncology INTRODUCTION: Alterations in expression and activity of human receptor tyrosine kinases (RTKs) are associated with cancer progression and in response to therapeutic intervention. METHODS: Thus, protein abundance of 21 RTKs was assessed in 15 healthy and 18 cancerous liver samples [2 primary and 16 colorectal cancer liver metastasis (CRLM)] matched with non-tumorous (histologically normal) tissue, by a validated QconCAT-based targeted proteomic approach. RESULTS: It was demonstrated, for the first time, that the abundance of EGFR, INSR, VGFR3 and AXL, is lower in tumours relative to livers from healthy individuals whilst the opposite is true for IGF1R. EPHA2 was upregulated in tumour compared with histologically normal tissue surrounding it. PGFRB levels were higher in tumours relative to both histologically normal tissue surrounding tumour and tissues taken from healthy individuals. The abundances of VGFR1/2, PGFRA, KIT, CSF1R, FLT3, FGFR1/3, ERBB2, NTRK2, TIE2, RET, and MET were, however, comparable in all samples. Statistically significant, but moderate correlations were observed (Rs > 0.50, p < 0.05) for EGFR with INSR and KIT. FGFR2 correlated with PGFRA and VGFR1 with NTRK2 in healthy livers. In non-tumorous (histologically normal) tissues from cancer patients, there were correlations between TIE2 and FGFR1, EPHA2 and VGFR3, FGFR3 and PGFRA (p < 0.05). EGFR correlated with INSR, ERBB2, KIT and EGFR, and KIT with AXL and FGFR2. In tumours, CSF1R correlated with AXL, EPHA2 with PGFRA, and NTRK2 with PGFRB and AXL. Sex, liver lobe and body mass index of donors had no impact on the abundance of RTKs, although donor age showed some correlations. RET was the most abundant of these kinases in non-tumorous tissues (~35%), while PGFRB was the most abundant RTK in tumours (~47%). Several correlations were also observed between the abundance of RTKs and proteins relevant to drug pharmacokinetics (enzymes and transporters). DISCUSSION: DiscussionThis study quantified perturbation to the abundance of several RTKs in cancer and the value generated in this study can be used as input to systems biology models defining liver cancer metastases and biomarkers of its progression. Frontiers Media S.A. 2023-02-20 /pmc/articles/PMC9986493/ /pubmed/36890818 http://dx.doi.org/10.3389/fonc.2023.1010563 Text en Copyright © 2023 Vasilogianni, Al-Majdoub, Achour, Peters, Rostami-Hodjegan and Barber https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Vasilogianni, Areti-Maria
Al-Majdoub, Zubida M.
Achour, Brahim
Peters, Sheila Annie
Rostami-Hodjegan, Amin
Barber, Jill
Proteomic quantification of receptor tyrosine kinases involved in the development and progression of colorectal cancer liver metastasis
title Proteomic quantification of receptor tyrosine kinases involved in the development and progression of colorectal cancer liver metastasis
title_full Proteomic quantification of receptor tyrosine kinases involved in the development and progression of colorectal cancer liver metastasis
title_fullStr Proteomic quantification of receptor tyrosine kinases involved in the development and progression of colorectal cancer liver metastasis
title_full_unstemmed Proteomic quantification of receptor tyrosine kinases involved in the development and progression of colorectal cancer liver metastasis
title_short Proteomic quantification of receptor tyrosine kinases involved in the development and progression of colorectal cancer liver metastasis
title_sort proteomic quantification of receptor tyrosine kinases involved in the development and progression of colorectal cancer liver metastasis
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986493/
https://www.ncbi.nlm.nih.gov/pubmed/36890818
http://dx.doi.org/10.3389/fonc.2023.1010563
work_keys_str_mv AT vasilogianniaretimaria proteomicquantificationofreceptortyrosinekinasesinvolvedinthedevelopmentandprogressionofcolorectalcancerlivermetastasis
AT almajdoubzubidam proteomicquantificationofreceptortyrosinekinasesinvolvedinthedevelopmentandprogressionofcolorectalcancerlivermetastasis
AT achourbrahim proteomicquantificationofreceptortyrosinekinasesinvolvedinthedevelopmentandprogressionofcolorectalcancerlivermetastasis
AT peterssheilaannie proteomicquantificationofreceptortyrosinekinasesinvolvedinthedevelopmentandprogressionofcolorectalcancerlivermetastasis
AT rostamihodjeganamin proteomicquantificationofreceptortyrosinekinasesinvolvedinthedevelopmentandprogressionofcolorectalcancerlivermetastasis
AT barberjill proteomicquantificationofreceptortyrosinekinasesinvolvedinthedevelopmentandprogressionofcolorectalcancerlivermetastasis